Kazia Therapeutics Appoints Scientific Architect Dr. Sudha Rao as CSO to Lead Oncology Platform
KZIA has more than doubled off its 52-week low of $2.86 on elevated volume (1.9× avg).
Summary
Kazia Therapeutics has appointed Dr. Sudha Rao as its new Chief Scientific Officer. Dr. Rao is a highly accomplished translational scientist and is noted as the scientific originator of the epigenetic framework underlying paxalisib and a pioneer in next-generation therapeutic platforms, including the SETDB1-targeted chromatin modulation program. This appointment follows Kazia's recent licensing of a novel SETDB1-targeted epigenetic platform from QIMR, where Dr. Rao holds a professorial appointment. Her expertise is expected to significantly strengthen the company's R&D capabilities, advance its pipeline, and support an integrated oncology platform strategy, which is a material development for this clinical-stage biotech.
At the time of this announcement, KZIA was trading at $10.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $107.2M. The 52-week trading range was $2.86 to $17.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.